XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Supplemental Financial Information (Tables)
9 Months Ended
Sep. 30, 2025
Other Balance Sheet Details [Abstract]  
Schedule of Inventories
Inventory consisted of the following:
(in millions)September 30,
2025
December 31,
2024
Raw materials$40.1 $33.7 
Work in process13.2 10.9 
Finished goods16.2 12.8 
69.5 57.4 
Less inventory reserves
(0.2)— 
Total inventory
$69.3 $57.4 
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following:
(in millions)September 30,
2025
December 31,
2024
Sales rebates and reserves$237.9 $144.2 
Accrued employee related costs105.1 107.5 
Accrued development costs
82.4 50.8 
Current branded prescription drug fee39.0 49.2 
Accounts payable and other accrued liabilities119.9 109.9 
Total accounts payable and accrued liabilities$584.3 $461.6 
Schedule of Other Noncurrent Liabilities
Other noncurrent liabilities consisted of the following:
(in millions)September 30,
2025
December 31,
2024
Noncurrent income taxes payable
$195.5 $160.7 
Other noncurrent liabilities
0.2 5.5 
Total other noncurrent liabilities$195.7 $166.2 
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions)September 30,
2025
September 30,
2024
Cash and cash equivalents$340.2 $349.1 
Restricted cash included in other noncurrent assets
8.0 8.0 
Total cash, cash equivalents, and restricted cash$348.2 $357.1